COPD Learning Series
From the hidden risk of small airways disease to practical optimisation of eligible patientsWebinar 1: Uncovering the hidden risk of small airways disease in COPD
This 2-part webinar series explores small airways disease and its impact on COPD, the role of extrafine formulation therapy, and practical steps to optimise eligible COPD patients in line with GOLD recommendations.
Small airways disease (SAD) is present in ~93% of symptomatic COPD patients¹ yet often goes undetected until late in disease progression²-⁴*. This webinar will uncover the “silent zone” of the lungs, its role in symptoms, exacerbations, and progression, and why timely optimisation of therapy is critical².
You can find out more about the hidden risk of small airways disease here.
Talk to us
Request a call or meeting with your local Chiesi representative at a time which suits you.
Order training inhalers
Support your patients with their inhaler technique by ordering placebo training inhalers directly from Chiesi.
Sign up for updates
Want to hear more from Chiesi? Opt-in to receive updates on Chiesi Air products and services.
References:
1. Crisafulli E, et al. Respiration. 2017; 93: 32–41.
2. Usmani OS, et al. Mayo Clin Proc. 2021; 96(9): 2448–2463.
3. Knox-brown B. The small airways, quiet no more. Available at: https://blogs.imperial.ac.uk/global-respiratory-health/2022/12/14/the-small-airways-quiet-no-more
4. Neder JA, et al. J Bras Pneumol. 2023; 48(6): e20220414.
* In an observational study (N=202); symptomatic COPD defined as CAT score ≥10.
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Chiesi Limited on 0800 0092329 (UK) or PV.UK@Chiesi.com.